Katarzyna Reszka
Lublin, LU 20093, Poland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Mutational landscapes of brain metastases across various histological subtypes of lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 27, 2025
Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases.
Journal: JTO clinical and research reports
Published: November 07, 2022
The efficacy of T790M mutation testing in liquid biopsy-Real clinic data.
Journal: PloS one
Published: October 07, 2021
Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement.
Journal: Scientific reports
Published: May 30, 2021
Impact of copy number variant and single nucleotide polymorphism of the programmed death-ligand 1 gene, programmed death-ligand 1 protein expression and therapy regimens on overall survival in a large group of Caucasian patients with non-small cell lung carcinoma.
Journal: Oncology letters
Published: November 04, 2020
Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients.
Journal: Frontiers in oncology
Published: May 19, 2020
PD-L1 gene copy number and promoter polymorphisms regulate PD-L1 expression in tumor cells of non-small cell lung cancer patients.
Journal: Cancer genetics
Published: January 23, 2019
Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer.
Journal: Archives of medical science : AMS
Published: December 12, 2018
Discrepancies between ALK protein disruption and occurrence of ALK gene rearrangement in Polish NSCLC patients.
Journal: Journal of thoracic disease
Published: September 21, 2018
Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
Journal: Advances in clinical and experimental medicine : official organ Wroclaw Medical University
Published: August 08, 2018
Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma.
Journal: Archives of medical science : AMS
Published: May 18, 2018
Last Updated: 09/26/2026